Eisai Co. Ltd. and Merck said FDA granted Breakthrough Therapy designation for Lenvima (lenvatinib), the orally available kinase inhibitor discovered by Eisai, in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the potential treatment of patients with advanced and/or metastatic non-microsatellite instability high/proficient mismatch repair endometrial carcinoma who have progressed following at least one prior systemic therapy.
Speaking on The Cancer Letter Podcast, Taofeek Kunle Owonikoko recalled recent conversations with two junior faculty members at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center.
